Literature DB >> 20486771

Microbead-assisted retroviral transduction for clinical application.

Bianca Heemskerk1, Annelies Jorritsma, Raquel Gomez-Eerland, Mireille Toebes, John B A G Haanen, Ton N M Schumacher.   

Abstract

Retroviral transduction is the most commonly used strategy to obtain long-term expression of therapeutic genes. To efficiently transduce mammalian cells, a recombinant fibronectin molecule, RetroNectin, is generally used to juxtapose viral particles and cells, and thereby enhance viral uptake. Although this strategy has become widely adopted, in particular for the genetic modification of hematopoietic cells, several limitations apply. For example, it requires the use of culture systems that allow protein coating, something that is not possible for many of the closed cell culture systems that are used in clinical trials. Furthermore, efficient transduction is obtained only when culture systems can be exposed to centrifugation, an approach termed spin transduction. Here, we describe a novel and more potent strategy for the transduction of T cells that can be applied on a clinical scale. We show that RetroNectin can efficiently be coated onto epoxy-modified paramagnetic beads. After a blocking step, these beads can subsequently bind retroviral particles from viral supernatants, rendering such supernatants largely devoid of functional viral particles. Addition of these virus-loaded beads to activated T cells results in efficient retroviral infection. Importantly, transduction does not require the use of culture systems that are compatible with protein coating, nor is it dependent on centrifugation of either the viral supernatant or the cells. Finally, cell growth, phenotype, and function of spin-transduced versus bead-transduced cells are comparable. Viral coating of microbeads should facilitate the production of genetically modified cells, in particular for use in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20486771     DOI: 10.1089/hum.2009.208

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  2 in total

1.  Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.

Authors:  Raquel Gomez-Eerland; Bastiaan Nuijen; Bianca Heemskerk; Nienke van Rooij; Joost H van den Berg; Jos H Beijnen; Wolfgang Uckert; Pia Kvistborg; Ton N Schumacher; John B A G Haanen; Annelies Jorritsma
Journal:  Hum Gene Ther Methods       Date:  2014-09-22       Impact factor: 2.396

2.  Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model.

Authors:  H Almåsbak; E Walseng; A Kristian; M R Myhre; E M Suso; L A Munthe; J T Andersen; M Y Wang; G Kvalheim; G Gaudernack; J A Kyte
Journal:  Gene Ther       Date:  2015-02-05       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.